Baird analyst Colleen Kusy raised the firm’s price target on Climb Bio (CLYM) to $12 from $9 and keeps an Outperform rating on the shares. The firm updated its model as all five of its studies are on track for readouts in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLYM: